Sanofi Consumer Healthcare India Limited has formally submitted its Annual Secretarial Compliance Report to the stock exchanges for the financial year ending December 31, 2025. The report, issued by M/s. BNP & Associates, confirms that the company has complied with the applicable statutory provisions and maintained proper corporate governance mechanisms throughout the review period. The report notes full compliance across all major regulatory areas examined.
Compliance Submission Overview
Sanofi Consumer Healthcare India Limited has officially filed the Annual Secretarial Compliance Report covering the financial year ended 31st December 2025. This submission is made pursuant to Regulation 24(A) of the relevant listing regulations, ensuring transparency regarding the company’s statutory adherence.
The report was prepared by the Secretarial Auditors, M/s. BNP & Associates, following a comprehensive review of the company’s records, filings, board processes, and adherence to various corporate statutes.
Key Compliance Findings for FY 2025
The review conducted by the Practicing Company Secretary (PCS) yielded a positive assessment across major compliance categories for the review period:
Statutory Adherence
- Secretarial Standards: The company was found to be in compliance with the requirements of Secretarial Standard 1 and Secretarial Standard 2 concerning meetings of the Board, its Committees, and General Meetings of Members.
- Policies and Governance: All applicable policies mandated under relevant regulations were adopted with due Board approval. Furthermore, these policies were reviewed and updated in conformity with the latest circulars and guidelines.
- Website Maintenance and Disclosure: The listed entity successfully maintains a functioning website. All required documents and information were disseminated timely, and web-links provided in the annual corporate governance reports were accurate and directed correctly.
Specific Regulatory Checks
- Director Disqualification: It was confirmed that no Director(s) of the Company were disqualified under Section 164 of the Companies Act, 2013.
- Subsidiaries: The review confirmed that the Company does not have any subsidiary company, rendering related identification and disclosure requirements inapplicable (marked as NA).
- Document Preservation: Records are being preserved and maintained as prescribed under SEBI regulations, with disposal managed according to the company’s Archival policy.
- Performance Evaluation: The required performance evaluation for the Board, Independent Directors, and Committees was conducted at the start of the financial year.
- Related Party Transactions (RPTs): The Audit Committee obtained prior approval for all RPTs, confirming compliance with necessary ratification procedures.
- Insider Trading: The company demonstrated compliance with Regulations 3(5) & 3(6) concerning the Prohibition of Insider Trading.
Actions and Observations
In respect of actions taken by regulatory bodies, no actions were taken by SEBI or the Stock Exchanges against the entity, its promoters, or directors during the review period.
Furthermore, the report confirmed no prior observations recorded in previous secretarial reports required remedial action during the current review period.
Auditor Confirmation
The Secretarial Auditors explicitly stated that their responsibility was limited to certifying compliance based on examination of documents provided, confirming that this process is neither an audit nor an expression of opinion on the future viability or management efficacy.
The report was signed by Nikunjkumar Savaliya, Company Secretary and Compliance Officer, on 1st March 2026, certifying the findings outlined by the PCS, BNP & Associates.
Source: BSE
